Pluristem Therapeutics Inc.
) recently announced its intention to commence a phase I study
that will evaluate the safety and efficacy of the local
administration of PLacental eXpanded (PLX) cells to patients
suffering from tendon injuries.
The randomized, double blind, placebo-controlled study will be
conducted as a part of the company's plan to expand its presence
in the orthopedic and sports medicine markets.
As per the American Academy of Orthopedic Surgeons, about 200,000
Americans require surgery related to repair of the rotator cuff
We note that Pluristem is conducting a phase I/II study
evaluating the safety and efficacy of its PLX cells in the
treatment of muscle injury. Safety is the primary endpoint of the
study while the secondary endpoint is the gluteal muscle function
after six months.
A positive outcome from this study will enable Pluristem to
further evaluate the potential of PLX cells for this indication
along with other non-surgical injuries such as sports injuries.
Pluristem develops placenta-based cell therapies. The cells from
placenta are derived using the company's proprietary PluriX
therapy. PluriX cells are a drug delivery platform that releases
a number of therapeutic proteins in response to various local and
systemic inflammatory and ischemic diseases.
Pluristem's first product in development, PLX-PAD, is intended to
treat peripheral artery disease (PAD).
Pluristem develops and manufactures cell therapy products in
collaboration with companies like
) or through research and clinical institutions.
Pluristem carries a Zacks Rank #3 (Hold). Currently, companies
Vertex Pharmaceuticals Incorporated
Transcept Pharmaceuticals, Inc.
) look more attractive with a Zacks Rank #1 (Strong Buy).
PLURISTEM THERA (PSTI): Free Stock Analysis
TRANSCEPT PHARM (TSPT): Get Free Report
UTD THERAPEUTIC (UTHR): Free Stock Analysis
VERTEX PHARM (VRTX): Free Stock Analysis
To read this article on Zacks.com click here.